For most of its life, Corcept Therapeutics was essentially a one-drug company. Korlym, its mifepristone pill for Cushing’s syndrome (a rare hormonal disorder where the body produces too much cortisol), built the whole business from scratch. Then, in early 2026, a second drug arrived. And almost simultaneously, generic competition cleared the runway to undercut the first. Two things that rarely happen at once, happening at once, is the story.
Before anything else
The 10-Q for the quarter ended June 30, 2026 shows Korlym still growing, a brand-new drug already generating real revenue, and full-year guidance raised sharply. The stock has more than tripled in six months, our data shows, pricing in a transition that has barely started. The open question is whether the new drug grows fast enough to replace what generics will eventually take.
The number that should not exist next to the other number
Korlym brought in $208.6 million in Q2 2026, up about 7% from the same quarter a year earlier, with record new prescriptions. In the same quarter, Corcept booked a net loss. A company setting prescription records and losing money in the same three months is not a contradiction you can ignore. The explanation is that Corcept spent heavily to launch its second drug, Lifyorli, approved in March 2026 for a form of ovarian cancer that stops responding to platinum-based chemotherapy. Launch costs front-load the income statement: the sales force is hired, the samples are shipped, the marketing runs, before the revenue catches up. That is the mechanical reason. Whether the revenue catches up fast enough is the whole question.
What Lifyorli’s first quarter actually says
Lifyorli (relacorilant) generated $47.6 million in its first full commercial quarter. For context, that is roughly what Korlym earns in three weeks. A new oncology drug at that level in quarter one is not a failure, but it is also not yet a replacement for a franchise doing roughly eight hundred million dollars a year. The math of the transition is simple to state and hard to execute: Lifyorli must compound its growth while Korlym’s generic erosion, expected to begin as early as late 2026 following a patent challenge in February 2026, subtracts from the other side of the ledger. The first few quarters of Lifyorli’s trajectory represent the most consequential data the company will produce for assessing the transition thesis.
The guidance revision as a signal
Management raised full-year 2026 revenue guidance to a range meaningfully above where it started the year, roughly a fifth higher at the midpoint than the original estimate. That is not a rounding adjustment. It implies the combined business is running well ahead of where Corcept itself expected at the start of the year. The company held $515.4 million in cash and equivalents as of March 31, 2026, enough to fund the launch spending without needing to raise money from outside investors, which matters because raising new money dilutes existing shareholders.
An 8-K filed September 23, 2026 also disclosed a planned leadership transition inside the Endocrinology division, effective October 1. The filing does not characterize it as a strategic pivot, but a division-level change at the exact moment Korlym faces its first generic threat is worth noting as a data point, not a verdict.
What the mood is paying for
The stock has risen more than 200% in six months, our data shows. That move compresses the math into a tight space. The trailing price-to-earnings ratio, the price a buyer pays for each dollar the company earned over the past year, sits far above this stock’s decade median, though the gap is partly an artifact: launch spending collapsed the earnings denominator, making the ratio look more extreme than the underlying business alone would justify. Still, the mood is clearly paying for a future where Lifyorli scales fast and Korlym’s decline is orderly. Filed numbers cannot yet confirm either assumption.
Reading the numbers
- Korlym Q2 2026 revenue: $208.6 million. What it is: net sales of the mifepristone pill for Cushing’s syndrome. What it means here: the legacy franchise is still growing at 7% year-over-year, but faces generic entry as early as late 2026. Everyday terms: a shop doing $200 a week in sales, still growing, but a competitor is about to open next door.
- Lifyorli Q2 2026 revenue: $47.6 million. What it is: first full commercial quarter for the new ovarian cancer drug. What it means here: a promising start, but roughly one-fifth of what Korlym earns in the same period. Everyday terms: a new branch office bringing in $47 while the flagship earns $208, in the same month.
- Cash position (March 31, 2026): $515.4 million. What it is: liquid reserves on the balance sheet. What it means here: enough runway to absorb launch losses without selling new shares. Everyday terms: a household with eight months of expenses saved before a big career transition.
- Full-year 2026 guidance: $1.1 billion to $1.2 billion. What it is: management’s own estimate of annual revenue. What it means here: raised sharply mid-year, signaling the combined business is tracking above internal expectations. Everyday terms: a contractor who quoted $950 in January and revised to $1,150 by July because the work came in faster than planned.
- Trailing P/E: 128.6 times (decade median: 32.5 times). What it is: price paid per dollar of recent earnings. What it means here: the ratio is inflated by a temporary earnings trough from launch costs, not purely by speculative richness, but the stock is still priced for a very specific outcome. Everyday terms: paying $128 for a business that earned $1 last year, when the same business historically traded at $33 per dollar earned.
Sources
- 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
- 10-Q, quarter ended March 31, 2026 (SEC EDGAR)
- Corcept Q2 2026 earnings release (BioSpace)
- Zacks via TradingView: Q2 earnings and guidance raise
- 8-K filed September 23, 2026 (StockTitan)
